TY - JOUR
T1 - Recent advances in nanotechnology-based COVID-19 vaccines and therapeutic antibodies
AU - Du, Lanying
AU - Yang, Yang
AU - Zhang, Xiujuan
AU - Li, Fang
N1 - Publisher Copyright:
© The Royal Society of Chemistry.
PY - 2022/1/28
Y1 - 2022/1/28
N2 - COVID-19 has caused a global pandemic and millions of deaths. It is imperative to develop effective countermeasures against the causative viral agent, SARS-CoV-2 and its many variants. Vaccines and therapeutic antibodies are the most effective approaches for preventing and treating COVID-19, respectively. SARS-CoV-2 enters host cells through the activities of the virus-surface spike (S) protein. Accordingly, the S protein is a prime target for vaccines and therapeutic antibodies. Dealing with particles with dimensions on the scale of nanometers, nanotechnology has emerged as a critical tool for rapidly designing and developing safe, effective, and urgently needed vaccines and therapeutics to control the COVID-19 pandemic. For example, nanotechnology was key to the fast-track approval of two mRNA vaccines for their wide use in human populations. In this review article, we first explore the roles of nanotechnology in battling COVID-19, including protein nanoparticles (for presentation of protein vaccines), lipid nanoparticles (for formulation with mRNAs), and nanobodies (as unique therapeutic antibodies). We then summarize the currently available COVID-19 vaccines and therapeutics based on nanotechnology.
AB - COVID-19 has caused a global pandemic and millions of deaths. It is imperative to develop effective countermeasures against the causative viral agent, SARS-CoV-2 and its many variants. Vaccines and therapeutic antibodies are the most effective approaches for preventing and treating COVID-19, respectively. SARS-CoV-2 enters host cells through the activities of the virus-surface spike (S) protein. Accordingly, the S protein is a prime target for vaccines and therapeutic antibodies. Dealing with particles with dimensions on the scale of nanometers, nanotechnology has emerged as a critical tool for rapidly designing and developing safe, effective, and urgently needed vaccines and therapeutics to control the COVID-19 pandemic. For example, nanotechnology was key to the fast-track approval of two mRNA vaccines for their wide use in human populations. In this review article, we first explore the roles of nanotechnology in battling COVID-19, including protein nanoparticles (for presentation of protein vaccines), lipid nanoparticles (for formulation with mRNAs), and nanobodies (as unique therapeutic antibodies). We then summarize the currently available COVID-19 vaccines and therapeutics based on nanotechnology.
UR - http://www.scopus.com/inward/record.url?scp=85123901070&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85123901070&partnerID=8YFLogxK
U2 - 10.1039/d1nr03831a
DO - 10.1039/d1nr03831a
M3 - Review article
C2 - 35018939
AN - SCOPUS:85123901070
SN - 2040-3364
VL - 14
SP - 1054
EP - 1074
JO - Nanoscale
JF - Nanoscale
IS - 4
ER -